Scalper1 News
Big-cap biotech and IBD 50 stock Gilead Sciences (GILD) said Monday that it’s licensing its megablockbuster hepatitis C drug Sovaldi to seven Indian generic-drug companies to improve access in 91 developing countries. Gilead’s stock fell about 2% on the stock market today. The Sovaldi licensing deal includes the big names in the Indian drug business, such as Ranbaxy Labs and Cipla, as well as U.S.-based Mylan (MYL). The drugmakers will be able to Scalper1 News
Scalper1 News